Triple-Negative Breast Cancer Update - Metastatic Breast Cancer Trial Talk

MBC News

For women and men with triple-negative breast cancer, chemotherapy has been the primary treatment option. But as scientists learn more about subtypes of triple-negative breast cancer, clinical trials can better match new targeted therapies with specific triple-negative patients. These advances are what led to the FDA approval in March 2019 of the PD-L1 inhibitor atezolizumab (Tecentriq®) to treat women and men with metastatic triple-negative breast cancer whose tumors test positive for PD-L1. And we can expect to see more trials that target specific subtypes of triple-negative cancer in the future.

Tags:

SEARCH OUR SITE

for past articles or specific information.